Tenaya Therapeutics, Inc. (TNYA) stock
Close on Nov 13, 2026Market cap $78.30MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $78.30M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.44
- Dividend yield
- –
- Free cash flow yield
- -69.79%
Fundamentals
- Net income
- -$101.78M
- EPS, diluted
- -$0.49
- Free cash flow
- -$54.65M
- Book value per share
- $0.24
- Diluted shares
- 226M
Trading
- Next earnings
- Mar 10, 2027 (estimated, after the close)
- Previous close
- $0.35
- Open
- $0.35
- Day's range
- $0.33 – $0.36
- Volume
- 1,307,649
- Average volume (20 days)
- 2,447,227
- Beta (5 years)
- 2.51
- 52-week range
- $0.30 – $1.54
- RSI (14 days)
- 36.8
- Volatility (1 year)
- 100.1%
- Relative volume
- 0.50×
- WACC
- 17.6%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | TNYA | S&P 500 | Difference | TNYA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -33.0% | -3.0% | −29.9 pts | ||
| 3 months | -52.4% | -2.8% | −49.6 pts | ||
| Year to date | -50.9% | +11.5% | −62.4 pts | ||
| 1 year | -74.5% | +13.5% | −88.0 pts | ||
| 3 years | -81.0% | +77.7% | −158.7 pts | -42.5% | +21.1% |
| 5 years | -98.7% | +72.6% | −171.3 pts | -58.0% | +11.5% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Tenaya Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Update
About Tenaya Therapeutics
Biological Products, (No Diagnostic Substances)
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops therapies targeting the underlying drivers of heart disease. Its lead product candidates include TN-201, an adeno-associated virus gene therapy in clinical trials for hypertrophic cardiomyopathy associated with MYBPC3 genetic variants, and TN-401, a gene therapy in clinical trials for arrhythmogenic right ventricular cardiomyopathy associated with PKP2 variants. The company also develops TN-301, a small molecule histone deacetylase 6 inhibitor investigated for heart failure with preserved ejection fraction and other disorders. Its target patient populations comprise individuals affected by rare genetic and prevalent cardiovascular conditions, and it collaborates with pharmaceutical partners.
Company profile, executives and historyTenaya Therapeutics stock: common questions
What is Tenaya Therapeutics's stock price?
TNYA closed at $0.35 on Nov 13, 2026, up 0.49% on the day. Over the past 52 weeks it traded between $0.30 and $1.54.
What is Tenaya Therapeutics's market cap?
Tenaya Therapeutics was worth $78.30M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is TNYA's P/E ratio?
Tenaya Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.49), so it has no meaningful P/E ratio.
Does Tenaya Therapeutics pay a dividend?
No. Tenaya Therapeutics has not paid a cash dividend over the last twelve months.
When does Tenaya Therapeutics report earnings next?
Tenaya Therapeutics is expected to report Q4 FY2026 results on Mar 10, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has TNYA stock performed over the past year?
Including dividends, TNYA returned -74.5% over the past year, against +13.5% for the S&P 500.
How many TNYA shares are sold short?
23M shares were sold short at the latest FINRA report, 14.05% of the float, or 8.7 days of average trading volume.
Who are Tenaya Therapeutics's competitors?
Companies most similar to Tenaya Therapeutics by business, industry and size include SLDB, FDMT, LXEO, TECX, SGMOQ.
See a number that looks wrong?